Ameliorative effect of LOTORIGA on memory in elderly with hyperlipidemia

Ameliorative effect of LOTORIGA on memory in elderly with hyperlipidemia - LOTORIGA study

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032734

Enrollment

Registered

2018-05-28

Start date

2013-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperlipidemia

Interventions

prescribe Rotriga 2g per day or 4g per day for 1 year observation without Rotriga for 1 year

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients diagnosed as having dyslipidemia (TG >= 150 mg/dl)

Exclusion criteria

Exclusion criteria: patients with hemorrhage, prescription of EPA drug, anticoagulants, NSAIDs excluding Aspirin, anti-acetylcholine esterase, supplements such as DHA or Beta-carotene

Design outcomes

Primary

Measure	Time frame
cognitive function test score (Mini-mental state examination, Hasegawa dementia scale-revised, Severe impairment Battery), evaluation at 6 & 12 month after drug administration	—

Secondary

Measure	Time frame
serum lipid (LDL-C, HDL-C, TG), BDNF, Erythrocyte membrane fatty acid composition, evaluation at 6 & 12 month after drug administration	—

Countries

Japan

Contacts

Public ContactMarina Ikeda

Shimane University, Faculty of Medicine Department of Internal Medicine III

cos3571@med.shimane-u.ac.jp0853202198

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026